Literature DB >> 11153672

An effective and safe protocol involving zidovudine and caesarean section to reduce vertical transmission of HIV-1 infection.

I Grosch-Wörner1, A Schäfer, M Obladen, R F Maier, K Seel, C Feiterna-Sperling, R Weigel.   

Abstract

OBJECTIVE: To investigate zidovudine prophylaxis with caesarean section to reduce mother-to-infant HIV transmission.
INTERVENTIONS: Elective caesarean section before labour, usually at 36-38 weeks of gestation, plus a short oral course of zidovudine, normally starting at week 32, intravenous zidovudine before caesarean section and for 10 days for the neonate (the reduced Berlin regimen).
RESULTS: Of 179 mother-infant pairs 104 received no antiretroviral prophylaxis or therapy (control group), 48 received the reduced Berlin prophylaxis regimen, 18 received combination therapy and nine received only part of the prophylaxis regimen. Of the antiretroviral group, 68 were delivered by elective caesarean section. The HIV transmission rate was zero in the antiretroviral group [95% confidence interval (CI) 0-4.7] and 12.6% (6.4-19.0) in the control group. The reduction in vertical transmission was 90% for the Berlin regimen, with an 80 and 70% reduction in risk associated with antiretroviral treatment and caesarean section, respectively. Maternal CD4 cell count but not viral load had some confounding effect on the reduction in risk attributed to caesarean section and the prophylactic regimen. Neonatal haematological abnormalities associated with antiretroviral intervention lasted for up to 7 weeks. Weight and length, although significantly lower at birth, were normal by 6-8 weeks.
CONCLUSION: A much reduced three-arm regimen of zidovudine prophylaxis in combination with caesarean section before labour is highly effective in reducing the risk of vertical HIV transmission and is safe for the infant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11153672     DOI: 10.1097/00002030-200012220-00012

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

Review 2.  Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

Authors:  Nila Bhana; Douglas Ormrod; Caroline M Perry; David P Figgitt
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 3.  Elective cesarean section for women living with HIV: a systematic review of risks and benefits.

Authors:  Caitlin E Kennedy; Ping T Yeh; Shristi Pandey; Ana P Betran; Manjulaa Narasimhan
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

4.  Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine.

Authors:  Jennifer Neubert; Maren Pfeffer; Arndt Borkhardt; Tim Niehues; Ortwin Adams; Mareike Bolten; Stefan Reuter; Hans Stannigel; Hans-Juergen Laws
Journal:  BMC Pregnancy Childbirth       Date:  2013-01-24       Impact factor: 3.007

5.  German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

Authors:  Bernd Buchholz; Matthias Beichert; Ulrich Marcus; Thomas Grubert; Andrea Gingelmaier; Annette Haberl; Brigitte Schmied
Journal:  Eur J Med Res       Date:  2009-11-03       Impact factor: 2.175

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.